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PolymorphismsAbstract Background: Research in the genetic basis of coronary artery diseases (CAD) has
identified some genes and pathways associated with diseases that would not be considered to under-
lie conventional risk factors. Among these genes there are the EGFR (epidermal growth factor
receptor) receptor family genes and the regulation factor genes (such as thyroid hormone receptor
a (THRA) and estrogen receptor a (ESR1)).
Aim: In this study we investigated the relation between 4 polymorphisms within EGFR, HER2
(human epidermal growth factor receptor 2), ESR1 and THRA genes and CAD.
Subjects and methods: The association analysis was performed with 151 healthy individuals and
151 CAD patients documented by angiography.
Results: No significant difference was found in the allelic and genotypic frequency distribution
of the four variants studied between the control and patient groups. We have also investigated the
relationship of these polymorphic sites with clinical and biochemical parameters such as smoking
habit, diabetes mellitus, hypertension, dyslipidemia, CAD severity, glucose, triglyceride, total
cholesterol and urea levels. The EGFR and THRA variants were associated with glycemia and
triglyceride levels, respectively. Also a significant correlation was found between the ESR1
polymorphism and the levels of urea and triglyceride.
Conclusion: Our results suggest the absence of any significant association between the four
polymorphisms analyzed and CAD risk as well as disease severity.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).diseases,
2 M. Rebaї et al.1. Introduction
Coronary artery disease (CAD) is a major cause of disability
and premature death worldwide [1]. CAD is a multifactorial
disease caused by genetic and environmental factors. Research
in the genetic basis of CAD has opened new perspectives in the
prevention and treatment of the common forms of this disease.
Even, it has radically changed the concepts of some diseases
origins. In fact, most of the genes that have been associated
with CAD have primarily been involved in biochemical path-
ways related to what are considered conventional risk factors.
However, recent genetic studies have begun to identify genes
and pathways associated with CAD that would not be consid-
ered to underlie conventional risk factors [2]. Among these
genes there are the EGFR receptor family genes and the regu-
lation factor genes (such as thyroid hormone receptor (TRa)
and estrogen receptor (ERa)).
The ErbB family (Erythroblastic leukemia viral oncogene
homolog) is composed of four plasma membrane bound recep-
tor tyrosine kinases, which are involved in molecular signaling
related to cell growth and survival in many tumor types [3].
The human epidermal growth factor receptor 1, known as
EGFR, is member of this receptor family. Previous studies
suggested that genetic polymorphisms in the EGFR gene had
been implicated in the susceptibility to some tumors [4] and
inflammatory diseases. More recently, EGFR has been impli-
cated in vascular pathophysiological processes associated with
excessive remodeling and atherosclerosis [5,6]. Thereafter,
polymorphisms of the EGFR gene have been associated with
acute coronary syndrome [7], dilated cardiomyopathy [8],
ischemic heart disease as well as arterial hypertension [9].
HER2 receptor is another member of EGFR family that has
long been associated with breast cancer development and pro-
gression. Targeting the HER2 receptor is a milestone in the
treatment of selected patients with early and advanced breast
cancer [10,11]. Anticancer efficacy is complicated by a new
type of heart failure [12–14]. There is evidence that trastuzu-
mab (or Herceptin is an anti-HER2 humanized monoclonal
antibody) [15,16], lapatinib (orally active drug for breast can-
cer which is a dual tyrosine kinase inhibitor interrupting the
HER2 and EGFR pathways) [17], and pertuzumab (mono-
clonal antibody that inhibits the HER2 dimerization) [18]
blocking the HER2-dependent signaling pathway may lead
to the deterioration of left ventricular cardiac function.
The receptors for thyroid hormone (TRa) and estrogen
(ERa) are prototypes of nuclear transcription factors that reg-
ulate the expression of target genes. These receptors are
encoded by THRA and ESR1 genes, respectively and were
found to be involved in CAD. In fact, thyroid receptors medi-
ate the action of thyroid hormones that play multiple biologi-
cal roles including effects on the cardiovascular system (lipid
profile, blood pressure and cardiac output). Moreover, the
expression of TRs is tissue-dependent and developmentally
regulated [19] and TRa is expressed predominantly in the
heart, bone, intestine, and brain. On the other hand, polymor-
phisms of the THRA gene have been associated with systolic
blood pressure and hypertension risk [20].
Estrogen receptor a is mainly expressed in endothelial cells,
vascular smooth muscle cells, and macrophages and plays anPlease cite this article in press as: Rebaї M et al., Association analysis of polymorp
Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.002important role in vascular wall physiology and function [21].
Many studies have suggested that common single nucleotide
polymorphisms (SNP) in the ESR1 gene have been associated
with an increased risk of vascular diseases, such as arterial
hypertension, cardiovascular diseases, alterations in serum
lipid levels, and cerebrovascular disease [22–24]. More
recently, it has been shown that genetic and epigenetic changes
in the ESR1 gene may enhance plasma cholesteryl ester forma-
tion and lead to its low levels and thereby have been associated
with cerebrovascular disease risk [25–27].
In this study, we report a case-control study in southern
Tunisia, investigating the association between CAD and four
genetic polymorphisms: R497K in the EGFR gene, I655V in
the HER2 gene, T594T in the ESR1 gene and CA repeat in
the THRA gene.2. Subjects and methods
2.1. Subjects and DNA isolation
Genomic DNA was extracted from blood samples of 151
healthy individuals (74 women and 77 men, with mean age
of 37 ± 19.8 years) and 151 CAD patients by a standard phe-
nol–chloroform method [28]. All subjects were from southern
Tunisia (Sfax region).
2.2. Patients’ profile and clinical data
We recruited between 2007 and 2008, 151 unrelated coronary
patients (95 women, 56 men, with mean age of 64 years),
who had symptomatic CAD: acute coronary syndrome or
stable angina, hospitalized at Cardiology Service of the Hedi
Chaker University Hospital of Sfax, Tunisia. Acute coronary
syndrome was diagnosed if at least one of the following criteria
was met: unstable angina (Electrocardiogram changes without
evidence of myocardial necrosis and clinical symptoms), acute
myocardial infarction (positive markers of myocardial necro-
sis) including ST-segment elevation myocardial infarction.
These patients underwent coronary angiography following
a myocardial infarction, angina, chest pain or heart failure.
After angiography, the group of patients (n= 64) with a
stenosis more than 50% on at least one major coronary artery
was divided into 3 subgroups according to the number of
affected coronary arteries. The absence of significant coronary
stenosis (650%) was designated (V0, n= 66).
After a detailed explanation of the purpose of the study, a
written informed consent was obtained from all patients. The
study protocol was approved by the local committee of
Medical Ethics (Hedi Chaker Hospital Ethics Committee,
Sfax). The work has been carried out in accordance with The
Code of Ethics of the World medical Association (Declaration
of Helsinki) for experiments in humans.
2.3. Biochemical analysis
Serum concentrations of glucose, triglycerides (TG), total
cholesterol and urea were measured by the standard methods
used in the clinical laboratory of the hospital.hisms in EGFR, HER2, ESR1 and THRA genes with coronary artery diseases,
Table 1 Frequency of R497K, I655V and T594T in the Tunisian population.
Gene Controls CAD patients Chi square
Count (%) Count (%) (p-value)
rs11543848 (R497K) EGFR
Genotype
AA 12 (7.95) 14 (9.27) 1.64 (0.44)
AG 47 (31.12) 56 (37.09)
GG 92 (60.93) 81 (53.64)
Allele
A 71 (23.51) 84 (27.81) 1.47 (0.22)
G 231 (76.49) 218 (72.18)
rs1801200 (I655V) HER2
Genotype
AA 84 (83.17) 123 (82) 0.06 (0.8)
AG 17 (16.83) 27 (18)
GG 0 (0) 0 (0)
Allele
A 185 (91.6) 273 (91) 9.13 (0.82)
G 17 (8.4) 27 (9)
rs2228440 (T594T) ESR 1
Genotype
AA 14 (9.27) 3 (3.3) 4.12 (0.12)
AG 44 (29.14) 34 (37.36)
GG 93 (61.59) 54 (59.34)
Allele
A 72 (23.84) 40 (21.98) 0.22 (0.63)
G 230 (76.16) 142 (78.02)
EGFR: epidermal growth factor receptor gene, HER2: Human Epidermal growth factor Receptor 2 gene, ESR1: estrogen receptor a gene, I:
isoleucine, V: valine, R: arginine, K: lysine, T: threonine, CAD: coronary artery diseases.
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The single nucleotide polymorphisms: rs11543848 (R497K) of
the EGFR gene, rs1801200 (I655V) of the HER2 gene and
rs2228440 (T594T) of the ESR1 gene (Table 2) were typed
by polymerase chain reaction (PCR) amplification using the
conditions described by Zhang et al. [29], Kalemi et al. [30]
and Akisik and Dalay [31], respectively, followed by restriction
enzyme digestion. The AC repeat of the THRA gene (accession
number NG_008493) was typed by Applied Biosystems
Automated Genetic Analysers (ABI3100-Avant) with Genscan
software (V3.5). PCR products of the reference THRA
sequence were 270 bp in length and contain 15 AC repeats
(using the conditions given by Shearman et al. [32]). All
PCR reactions were performed by using a GenAmp PCR sys-
tem 9600 thermocycler (Perkin–Elmer).
2.5. Statistical analysis
The genotypic frequencies were calculated by simple counting
using Microsoft-Excel. The estimation of allele frequency and
exact test for Hardy–Weinberg equilibrium was performed
using the Genetic Data Analyses program (version 1.1) [33].
Genotypic and allelic frequencies were compared between con-
trols and patients using standard chi square test at a 5% level
of significance. For comparing microsatellite allelic frequencies
between controls and patients we also used the Clump pro-
gram [34]. This program proposes different tests and provides
p-values that are corrected for multiple testing. Odds ratio for
the case–control association study and their 95% confidencePlease cite this article in press as: Rebaї M et al., Association analysis of polymorp
Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.002intervals were estimated using programs from Linkage Utility
Package (http://linkage.rockefeller.edu). In patients with
CAD, correlation between the genotypes and clinicopatholog-
ical characteristics was carried out with the SPSS program
(version 21.0).
3. Results
3.1. Association between polymorphisms and CAD
3.1.1. Association analysis of the I655V, R497K and T594T
polymorphisms
Allelic and genotypic frequencies of the HER2 I655V, EGFR
R497K and ESR1 T594T polymorphisms in CAD patients and
healthy individuals are given in Table 1. No significant devia-
tion from Hardy–Weinberg equilibrium was found for any of
the SNPs studied (p= 0.137, p= 0.086 and p= 0.2 for the
R497K, I655V and T594T polymorphisms, respectively). The
allelic and genotypic frequencies of the 3 SNPs were similar
in the patient and control groups, and the difference between
the frequencies was not statistically significant (Table 1).
When the three polymorphisms are tested together by bin-
ary logistic regression, no association was found with any of
them.
3.2. Association analysis of the THRA repeat polymorphism
THRA repeat was successfully genotyped in 150 healthy unre-
lated individuals and 147 individuals with CAD. The level of
heterozygosity was estimated as 81.9%. Hardy–Weinberghisms in EGFR, HER2, ESR1 and THRA genes with coronary artery diseases,
Table 2 THRA microsatellite and cardiovascular disease risk in the Tunisian population.
Controls Patients Chi square OR (95% CI)
Count (%) Count (%) (p-value)
Alleles
S (620) 215 (71.67) 189 (64.3) 3.712 (0.053) 0.71 (0.5–1.01)
L (>20) 85 (28.33) 105 (35.7)
Genotypes
SS 78 (52) 65 (44.22) 1.8 (0.179) 0.73 (0.49–1.16)
SL 59 (39.3) 59 (40.14) 0.019 (0.95) 1.03 (0.65–1.65)
LL 13 (8.7) 23 (15.64) 3.39 (0.065) 1.95 (0.95–4.02)
THRA: thyroid hormone receptor a gene, OR: odd ratio, S: short alleles (620 repeats), L: long allele (>20 repeats).
4 M. Rebaї et al.equilibrium was satisfied (exact p= 0.06). Forty-five geno-
types (14 alleles) were found in the Tunisian control group
against 42 genotypes (13 alleles) in patients. The most preva-
lent genotype was 18/20 (15.3% and 16.3% in controls and
CAD patients, respectively) whereas most of the genotypes
had a frequency less than 5%. The allelic frequencies were very
similar between patients and controls, and no significant differ-
ence was found when comparing all alleles by Clump
(p= 0.33) or each individual allele separately. Also, if we
define two classes of alleles, S (short) for alleles with 620
repeats and L (long) for >20, no significant association was
found (p= 0.053) (Table 2).
3.3. Association of polymorphisms with clinical and biochemical
parameters
The analysis of possible association of the genotype polymor-
phisms with the clinical and biochemical parameters of CAD
showed five significant associations (Table 3). The first is
between the SNP R497K of the EGFR gene and the glycemia
level (p= 0.008). A high level of glycemia is correlated with
the presence of AG genotype. The second is between the
THRA microsatellite and the TG serum level (p= 0.0024).
Subjects with LL genotypes have the lowest serum levels of
TG. The others, are between the SNP T594T of the ESR1 gene
and the smoking habit (p= 0.002) as well as urea (p= 0.037)
and TG (p= 0.019) levels. The genotypes AG and GG were
more prevalent among nonsmokers and were associated with
high TG and urea levels, respectively.
Also, multivariate analysis was performed using the clinical
or biochemical parameter as dependent variable and the mark-
ers’ genotypes as explanatory variables adjusted for other clin-
ical and biochemical variables. But, no significant association
was found for the four polymorphisms (p> 0.05).4. Discussion
In the present study, we examined the possibility of association
between CAD and four polymorphisms in a southern Tunisian
sample: R497K polymorphism of the EGFR gene, I655V poly-
morphism of the HER2 gene, T594T polymorphism of the
ESR1 gene and the microsatellite D17S2189 of the THRA
gene with CAD. Distribution of allele or genotype frequencies
of the four polymorphisms in our case-control sample does not
reveal any significant association, and this finding persisted
after adjusting for several potential confounding factors.Please cite this article in press as: Rebaї M et al., Association analysis of polymorp
Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.002However, analyzing the relationship between the 4 poly-
morphisms and the clinical and biochemical parameters of
our cohort, a significant association was found between the
SNP R497K and the glycemia level. A high level of glycemia
was correlated with the presence of AG genotype. The role
of this polymorphic site in CAD was established in many stud-
ies where it was associated with the risk of acute coronary syn-
drome [7] and dilated cardiomyopathy [8] in a Chinese
population. These authors suggested that genetic polymor-
phism of EGFR (Arginine? Lysine) might be clinically
important in the development and progression of these dis-
eases but the exact mechanism by which the Lys allele may
act is unclear. In 1993, a variant EGFR of an arginine to lysine
substitution at codon 497 was identified [35]. Wild-type EGFR
(Arg allele) differs from mutant EGFR (Lys allele) with
respect to epithelial proliferation following the administration
of EGF and TGF-a in rodents [36]. Thus, it was suggested that
mutations which influence the function or expression of EGFR
(such as attenuating its ligand binding as well as subsequent
activation of its downstream effectors) might predispose to
development of some diseases and phenotypes.
Also, a significant association was observed between the
THRA microsatellite and the TG serum level. Subjects with
LL genotypes possess the lowest serum level of TG. This result
suggest that long allele of this microsatellite may have a pro-
tective effect against TG increases. To our knowledge, this is
the first time that this polymorphic site was investigated for
an association study with CAD. However, the relationship
between this genetic variant and thyroid cancer risk was inves-
tigated in many studies [37–39] and it was suggested in a study
performed on a Japanese population, that less aggressive thy-
roid cancer is correlated with increased THRA expression and
an expanded THRA microsatellite [37]. These authors have
suggested also that the size of this microsatellite can have an
influence on the splicing phenomenon and on the expression
of THRA isoforms based on the fact that the THRA repeat
polymorphism is located in exon 9, near a splice junction.
Likewise, our results showed a significant correlation
between the SNP T594T of the ESR1 gene and the smoking
habit as well as urea and TG levels. The genotypes AG and
GG were more prevalent among nonsmokers and were associ-
ated with high TG and urea levels, respectively. This result
suggests the importance of ER in CAD via its association with
some classical risk factors including smoking, high TG and
urea levels. The effects of estrogen on the cardiovascular sys-
tem, mediated mainly by ERa, have been well defined and
specific polymorphisms in the ESR1 gene have been associatedhisms in EGFR, HER2, ESR1 and THRA genes with coronary artery diseases,
Table 3 Association results of polymorphisms genotypes with clinical and biochemical parameters.
Characteristic Number (Genotype frequency%)
R497K (EGFR) I655V (HER2) T594T (ESR1) D17S2189 (THRA)
AA AG GG AA AG GG AA AG GG SS SL LL
Clinical and anthropometric parameters
Sex
Female 9 (9.6) 32 (34) 53 (56.4) 74 (79.6) 19 (20.4) 0
(0)
1 (2) 23 (46) 26 (52) 38 (40.4) 44 (46.8) 12 (12.8)
Male 4 (7.1) 24 (42.8) 28 (50) 48 (87.3) 7 (12.7) 0
(0)
2 (5.1) 9 (23.07) 28 (71.8) 26 (49.05) 15 (28.3) 12 (22.64)
p-valueb 0.566 0.27 0.06 0.062
Age (years) 63.3 ± 2.57 61.56
± 1.75
65.26 ± 1.29 64.51 ± 0.93 62.35 ± 2.99 0 67.33
± 5.48
63.77
± 1.85
66.81
± 1.21
63.19
± 1.53
63.12 67.25
± 1.96
p-valuea 0.58 0.504 0.495 0.591 0.934 0.978 0.109
Smoking habit
Smoker 1 (3.44) 13 (44.83) 15 (51.72) 23 (79.3) 6 (20.7) 0
(0)
2 (8.69) 2 (8.69) 19 (82.6) 16 (57.14) 8 (28.57) 4 (14.28)
Not smoker 12 (11.21) 43 (40.18) 64 (59.81) 97 (82.9) 20 (17.1) 0
(0)
1 (1.53) 29 (44.61) 35 (53.84) 47 (40.51) 49 (42.24) 20 (17.24)
p-valueb 0.525 0.6 0.002 0.293
Diabete mellitus
Diabetic 4 (6.77) 25 (42.3) 30 (50.84) 46 (80.7) 11 (19.3) 0
(0)
2 (4.25) 18 (38.3) 27 (57.44) 27 (48.21) 19 (33.93) 10 (17.86)
Not diabetic 9 (10.23) 31 (35.23) 48 (54.54) 73 (83) 15 (17) 0
(0)
1 (2.43) 13 (31.7) 27 (65.85) 36 (41.38) 37 (42.53) 14 (16.09)
p-valueb 0.609 0.731 0.679 0.614
Hypertension
Hypertensive 7 (8.23) 37 (43.53) 41 (48.23) 70 (84.3) 13 (15.7) 0
(0)
2 (3.92) 20 (39.21) 29 (56.86) 31 (38.27) 33 (40.74) 17 (20.99)
Not hypertensive 1 (14.28) 3 (42.86) 4 (57.14) 8 (100) 0 (0) 0
(0)
0 (0) 1 (50) 1 (50) 6 (75) 2 (25) 0 (0)
p-valueb 0.748 0.596 1 0.156
DBP (mmHg) 139.09
± 5.79
143.9
± 3.98
149.48
± 3.38
140.56
± 2.79
147.05
± 7.01
0 150
± 15.27
142.63
± 5.18
146.1
± 3.65
151.76
± 3.68
142.1 ± 4 148.26
± 4.97
p-value 0.501 0.139 0.396 0.685 0.825 0.079 0.574
SBP (mmHg) 80.9 ± 3.92 81.11 ± 2.5 81.11 ± 1.93 87.1 ± 2.32 87.03 ± 3.98 0 76.66 ± 12 76.89
± 2.43
81.6 ± 2.65 83.83
± 2.25
78.9
± 2.34
81.95
± 2.96
p-valuea 0.966 0.962 0.989 0.987 0.724 0.133 0.616
Dyslipidemia
Positive 7 (16.28) 14 (32.56) 22 (51.16) 34 (82.9) 7 (17.1) 0
(0)
2 (5.88) 16 (47.06) 16 (47.06) 20 (48.78) 15 (36.58) 6 (14.63)
Negative 6 (5.77) 42 (40.38) 56 (53.84) 85 (81.7) 19 (18.3) 0
(0)
1 (1.85) 15 (17.78) 38 (70.37) 43 (42.57) 41 (40.19) 18 (17.64)
p-valueb 0.122 1 0.067 0.803
CAD severity*
v0 5 (7.57) 23 (34.84) 38 (57.57) 54 (80.6) 13 (19.4) 0
(0)
1 (4.34) 8 (34.8) 14 (60.86) 25 (37.31) 30 (44.77) 12 (17.91)
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Table 3 (continued)
Characteristic Number (Genotype frequency%)
R497K (EGFR) I655V (HER2) T594T (ESR1) D17S2189 (THRA)
AA AG GG AA AG GG AA AG GG SS SL LL
v1 5 (11.11) 17 (37.78) 23 (51.11) 38 (88.4) 5 (11.6) 0
(0)
1 (2.63) 12 (31.58) 25 (65.8) 23 (56.1) 11 (26.83) 7 (17.07)
v2 2 (25) 4 (50) 2 (25) 6 (75) 2 (25) 0
(0)
0 (0) 4 (50) 4 (50) 3 (42.85) 3 (42.85) 1 (14.28)
v3 1 (10) 4 (40) 6 (60) 9 (81.8) 2 (18.2) 0
(0)
1 (11.11) 1 (11.11) 7 (77.77) 5 (45.45) 5 (45.45) 1 (9.09)
p-valueb 0.566 0.626 0.539 0.555
Biochemical parameters
Fasting glucose (lmol/l) 5.83 ± 0.81 9.05 ± 0.76 12 ± 4.24 10.82 ± 2.32 6.52 ± 0.44 0 11.45
± 4.55
8.51 ± 1.09 13.98
± 5.41
8.4 ± 0.63 7.72
± 0.62
7.82 ± 1.09
p-valuea 0.008 0.16 0.073 0.634 0.733 0.447 0.652
Urea (lmol/l) 9.31 ± 2.69 8.47 ± 1.05 7.04 ± 0.49 7.79 ± 0.47 9.28 ± 1.87 0 5.72 ± 0.77 10.37
± 1.89
7.02 ± 0.52 8.35 ± 1.03 7.82
± 0.71
6.87 ± 0.94
p-valuea 0.778 0.436 0.451 0.037 0.293 0.525 0.3
Triglyceride (mmol/l) 2.02 ± 0.19 1.67 ± 0.14 2.06 ± 0.26 1.9 ± 0.14 1.83 ± 0.23 0 1.28 ± 0.03 1.61 ± 0.17 1.98 ± 0.27 1.76 ± 0.14 2.18
± 0.29
1.3 ± 0.12
p-valuea 0.175 0.907 0.802 0.09 0.019 0.218 0.024
Total cholesterol
(mmol/l)
4.85 ± 0.45 13.48
± 8.42
8.01 ± 2.23 9.72 ± 3.29 4.42 ± 0.84 0 5.11 ± 0.36 4.98 ± 0.46 8.17 ± 2.48 5.99 ± 0.58 15.02
± 10
4.99
± 0.676
p-valuea 0.3219 0.175 0.124 0.835 0.235 0.381 0.278
DBP: diastolic blood pressure, SBP: systolic blood pressure, EGFR: epidermal growth factor receptor gene, HER2: human epidermal growth factor receptor 2 gene, ESR1: estrogen receptor a gene,
THRA: thyroid hormone receptor a gene, I: isoleucine, V: valine, R: arginine, K: lysine, T: threonine.
Significant associations are in bold.
* Based on number of affected coronary arteries: stenosis <50% of one (V0), P50% of one (V1), two (V2), or three (V3) major coronary arteries.
a p-value of student’s t-test of mean comparison with AA genotype as a reference group.
b p-value of Fisher’s exact test.
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Coronary artery diseases and genetics 7with several coronary heart diseases including CAD, hyperten-
sion and stroke in studies covering different populations
[24,40,41]. Although that the SNP T594T is synonymous and
yields no change in protein sequence, its importance has been
highlighted in many investigations where it has been suggested
that the mechanism of action may involve alternative gene reg-
ulation and transcript processing [39,42].
Regarding the SNP I655V of the HER 2 gene and despite
the absence of significant association in our study, the impor-
tance of this polymorphism has been highlighted in many stud-
ies and according to the secondary structure prediction of the
transmembrane domain, it has been suggested that the pres-
ence of the I residue at position 655 might destabilize the for-
mation of active HER2 dimers and reduce phosphotyrosine
kinase activity even in the presence of receptor overexpression
[43]. More recently, Pinto et al. [44] have suggested that the
genotype GG confers high heterodimerization capacities to
the receptor that can activate more powerfully the intracellular
signaling pathways of HER2 such as MAPK and PI3P/AKT.
The involvement of the HER2 receptor in CAD has been
revealed in many studies. In a recent study, the authors showed
an association between a decreased expression of ErbB2/
HER2 and the release of troponins and the need for inotropic
therapy in patients with acute heart failure and they conclude
that the molecular function of the HER2 receptor may be
essential for the prognosis and targeted therapy of heart dis-
eases [45]. Also, it has been shown that targeting the HER2
receptor in the anticancer therapy may lead to the deteriora-
tion of left ventricular cardiac function [11]. Later, the SNP
I655V has been associated with cardiac toxicity in breast can-
cer patients treated with Trastuzumab [46].5. Conclusion
Our results suggest the absence of any significant association
between the four genetic variants analyzed and CAD risk as
well as disease severity. However, these polymorphic sites
may be involved in such diseases indirectly through the inter-
mediary of their association with some classic risk factors such
as smoking habit, glycemia, urea and TG levels. These results
are encouraging to conduct advanced studies evaluating with
precision the role of these genetic variants and their respective
genes in CAD.Acknowledgements
This work was supported by the Ministry of Higher Education
and Scientific Research, Tunisia.References
[1] World Health Organization Global Health Estimates: Deaths by
Cause, Age, Sex and Country, 2000–2012. Geneva WHO; 2014.
[2] Tymchuk CN, Hartiala J, Patel PI, et al. Nonconventional genetic
risk factors for cardiovascular disease. Curr Atheroscler Rep
2006;8(3):184–92.
[3] Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB
receptor-targeted anticancer therapeutics is influenced by the
availability of epidermal growth factor-related peptides. Cancer
Res 2002;62(11):3151–8.Please cite this article in press as: Rebaї M et al., Association analysis of polymorp
Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.002[4] Prenzel N, Fischer OM, Streit S, et al. The EGF receptor family as
a central element for cellular signal transduction and diversifica-
tion. Endocr Relat Cancer 2001;8:11–31.
[5] Berk BC. Vascular smooth muscle growth: autocrine growth
mechanisms. Physiol Rev 2001;81:999–1030.
[6] Kalmes A, Daum G, Clowes AW. EGFR transactivation in the
regulation of SMC function. Ann N Y Acad Sci 2001;947:42–54.
[7] Gao LB, Zhou B, Zhang L, et al. R497K polymorphism in
epidermal growth factor receptor gene is associated with the risk
of acute coronary syndrome. BMC Med Genet 2008;9:74.
[8] Zhou B, Rao L, Peng Y, et al. Epidermal growth factor receptor
gene polymorphisms, R497K, but not (CA)n repeat, is associated
with dilated cardiomyopathy. Clin Chim Acta 2009;403(1–
2):184–7.
[9] Makeeva OA, Sleptsov AA, Kulish EV, et al. Genomic study of
cardiovascular continuum comorbidity. Acta Nat 2015;7
(3):89–99.
[10] Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a
milestone in the treatment of HER-2-positive early breast cancer.
Oncologist 2006;11(S1):4–12.
[11] Nielsen DL, Ku¨mler I, Palshof JA, et al. Efficacy of HER2-
targeted therapy in metastatic breast cancer. Monoclonal anti-
bodies and tyrosine kinase inhibitors. Breast 2013;22(1):1–12.
[12] Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do
we know? Clin Breast Cancer 2008;8(S3):S114–20.
[13] Cheng H, Force T. Molecular mechanisms of cardiovascular
toxicity of targeted cancer therapeutics. Circ Res 2010;106:21–34.
[14] Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel
HER2-targeted therapies. Curr Med Res Opin 2013;29
(8):1015–24.
[15] Russell SD, Blackwell KL, Lawrence J, et al. Independent
adjudication of symptomatic heart failure with the use of
doxorubicin and cyclophosphamide followed by trastuzumab
adjuvant therapy: a combined review of cardiac data from the
National Surgical Adjuvant Breast and Bowel Project B-31 and
the North Central Cancer Treatment Group N9831 clinical trials.
J Clin Oncol 2010;28(21):3416–21.
[16] Criscitiello C, Curigliano G. HER2 signaling pathway and
trastuzumab cardiotoxicity. Future Oncol 2013;9(2):179–81.
[17] Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib:
pooled analysis of 3689 patients enrolled in clinical trials. Mayo
Clin Proc 2008;83(6):679–86.
[18] Lenihan D, Suter T, Brammer M, et al. Pooled analysis of cardiac
safety in patients with cancer treated with pertuzumab. Ann Oncol
2012;23(3):791–800.
[19] Cheng SY. Multiple mechanisms for regulation of the transcrip-
tional activity of thyroid hormone receptors. Rev Endocr Metab
Disord 2000;1:9–18.
[20] Goumidi L, Gauthier K, Legry V, et al. Association between a
thyroid hormone receptor-a gene polymorphism and blood
pressure but not with coronary heart disease risk. Am J Hypertens
2011;24(9):1027–34.
[21] Nakase T, Yamazaki T, Ogura N, et al. The impact of
inflammation on the pathogenesis and prognosis of ischemic
stroke. J Neurol Sci 2008;271:104–9.
[22] Shearman AM, Cupples LA, Demissie S, et al. Association
between estrogen receptor alpha gene variation and cardiovascu-
lar disease. JAMA 2003;290:2263–70.
[23] Carter CJ. Convergence of genes implicated in Alzheimer’s disease
on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins,
and atherosclerosis. Neurochem Int 2007;50:12–38.
[24] Ding J, Xu H, Yin X, et al. Estrogen receptor a gene PvuII
polymorphism and coronary artery disease: a meta-analysis of 21
studies. J Zhejiang Univ Sci B 2014;15(3):243–55.
[25] Li BH, Zhang LL, Yin YW, et al. Association between estrogen
receptor alpha c.454-397T > C and c.454-351A>G and
ischemic stroke risk: a systematic review and metaanalysis. Mol
Biol Rep 2012;39:9331–8.hisms in EGFR, HER2, ESR1 and THRA genes with coronary artery diseases,
8 M. Rebaї et al.[26] Markoula S, Milionis H, Lazaros L, et al. Associations of ESR2
AluI (G/A) polymorphism with ischemic stroke in Caucasians. J
Neurol Sci 2012;316:126–30.
[27] Gao HH, Gao LB, Wen JM. Genetic polymorphisms in the ESR1
gene and cerebral infarction risk: a meta-analysis. DNA Cell Biol
2014;33(9):605–15.
[28] Sambrook J, Russell I. Molecular cloning: a laboratory manual.
Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press;
2001.
[29] Zhang W, Park DJ, Lu B, et al. Epidermal growth factor receptor
gene polymorphisms predict pelvic recurrence in patients with
rectal cancer treated with chemoradiation. Clin Can Res
2005;600:600–5.
[30] Kalemi TG, Lambropoulos AF, Gueorguiev M, et al. The
association of p53 mutations and p53 codon 72, Her 2 codon
655 and MTHFR C677T polymorphisms with breast cancer in
Northern Greece. Cancer Lett 2005;222:57–65.
[31] Akisik E, Dalay N. Estrogen receptor codon 594 and HER2
codon 655 polymorphisms and breast cancer risk. Exp Mol Path
2004;7:6260–3.
[32] Shearman AM, Demissie S, Cupples LA, et al. Tobacco smoking,
estrogen receptor a gene variation and small low density lipopro-
tein level. Hum Mol Gen 2005;14(16):2405–13.
[33] Weir BS. Genetic data analysis. Sunderland, MA: Sinauer
Associates; 1996.
[34] Sham PC, Curtis D. Monte Carlo tests for associations between
disease and alleles at highly polymorphic loci. Ann Hum Genet
1995;59:97–105.
[35] Moriai T, Kobrin MS, Korc M. Cloning of a variant epidermal
growth factor receptor. Biochem Biophys Res Commun
1993;191:1034–9.
[36] Moriai T, Kobrin MS, Hope C, et al. A variant epidermal growth
factor receptor exhibits altered type a transforming growth factor
binding and transmembrane signaling. Proc Natl Acad Sci USA
1994;91:10217–21.Please cite this article in press as: Rebaї M et al., Association analysis of polymorp
Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.08.002[37] Onda M, Li D, Suzuki S, et al. Expansion of microsatellite in the
thyroid hormone receptor-a1 gene linked to increased receptor
expression and less aggressive thyroid cancer. Clin Cancer Res
2002;8:2870–4.
[38] Baida A, Farrington SM, Galofre P, et al. Thyroid cancer
susceptibility and THRA1 and BAT-40 repeat polymorphisms.
Can Epi Biomar Prev 2005;14(3):638–42.
[39] Rebaı¨ M, Kallel I, Charfeddine S, et al. Association of polymor-
phisms in estrogen and thyroid hormone receptors with thyroid
cancer risk. J Recept Signal Transduct Res 2009;29(2):113–8.
[40] Aouizerat BE, Vittinghoff E, Musone SL, et al. GWAS for
discovery and replication of genetic loci associated with sudden
cardiac arrest in patients with coronary artery disease. BMC
Cardiovasc Disord 2011;11:29.
[41] de Las Fuentes L, Sung YJ, Schwander KL, et al. The role of
SNP-loop diuretic interactions in hypertension across ethnic
groups in HyperGEN. Front Genet 4 304.
[42] Weickert CS, Miranda-Angulo AL, Wong J, et al. Variants in the
estrogen receptor alpha gene and its mRNA contribute to risk for
schizophrenia. Hum Mol Genet 2008;17(15):2293–309.
[43] Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-
activation switch in the transmembrane domain of erbB2. Proc
Natl Acad Sci USA 2002;99:15937–40.
[44] Pinto D, Pereira D, Portela C, et al. The influence of HER2
genotypes as molecular markers in ovarian cancer outcome.
Biochem Biophys Res Commun 2005;335:1173–8.
[45] Szmit S, Jank M, Maciejewski H, et al. Relationship between
clinical data and gene expression in the HER2/ErbB2-dependent
signaling pathway in patients with acute heart failure. J Appl
Genet 2013;54(4):447–53.
[46] Lemieux J, Diorio C, Coˆte´ MA, et al. Alcohol and HER2
polymorphisms as risk factor for cardiotoxicity in breast cancer
treated with trastuzumab. Anticancer Res. 2013;33(6):2569–76.hisms in EGFR, HER2, ESR1 and THRA genes with coronary artery diseases,
